Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
William G WierdaJohn N AllanTanya SiddiqiThomas J KippsStephen Samuel OpatAlessandra TedeschiXavier C BadouxBryone J KussSharon JacksonCarol MorenoRyan JacobsJohn M PagelIan W FlinnYvonne PakCathy ZhouEdith Szafer-GlusmanJoi NinomotoJames P DeanDanelle F JamesPaolo GhiaConstantine S TamPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The 1-year DFS rate of 95% in placebo-randomly assigned patients with Confirmed uMRD suggests the potential for fixed-duration treatment with this all-oral, once-daily, chemotherapy-free regimen in first-line CLL.